

**IL32 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP14500a****Specification**

---

**IL32 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [P24001](#)**IL32 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 9235**Other Names**

Interleukin-32, IL-32, Natural killer cells protein 4, Tumor necrosis factor alpha-inducing factor, IL32, NK4, TAIF

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**IL32 Antibody (N-term) Blocking Peptide - Protein Information****Name** IL32**Synonyms** NK4, TAIF**Function**

Cytokine that may play a role in innate and adaptive immune responses. It induces various cytokines such as TNFA/TNF-alpha and IL8. It activates typical cytokine signal pathways of NF-kappa-B and p38 MAPK.

**Cellular Location**

Secreted.

**Tissue Location**

Selectively expressed in lymphocytes. Expression is more prominent in immune cells than in non-immune cells

**IL32 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **IL32 Antibody (N-term) Blocking Peptide - Images**

#### **IL32 Antibody (N-term) Blocking Peptide - Background**

This gene encodes a member of the cytokine family. The protein contains a tyrosine sulfation site, 3 potential N-myristoylation sites, multiple putative phosphorylation sites, and an RGD cell-attachment sequence. Expression of this protein is increased after the activation of T-cells by mitogens or the activation of NK cells by IL-2. This protein induces the production of TNFalpha from macrophage cells. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

#### **IL32 Antibody (N-term) Blocking Peptide - References**

Li, W., et al. J. Immunol. 185(9):5056-5065(2010) Cho, K.A., et al. Microb. Pathog. 49(3):95-104(2010) Kobori, A., et al. World J. Gastroenterol. 16(19):2355-2361(2010) Yue, D., et al. Asian J. Androl. 12(3):381-389(2010) Chae, J.I., et al. Cell. Immunol. 264(1):47-53(2010)